Table 1.
Examples of drug delivery systems in oncology and their stage of development
|
Passive targeting | |||
|---|---|---|---|
| Name | Platform | Compound | Clinical stage |
| NK105 | Micelles | Paclitaxel | P2 |
| NC‐6004 | Micelles | Cisplatin | P1/2 |
| NK012 | Micelles | SN‐38 | P2 |
| Smancs | Polymer conjugate | Neocarzinostatin | Approved |
| Doxil | Liposome | Doxorubicin | Approved |
| Abraxane | Albumin particle | Paclitaxel | Approved |
| Xyota,˜ | Polymer conjugate | Paclitaxel | P3 |
| CT‐2106 | Polymer conjugate | Camptothecin | P2 |
| EndoTAG | Cationic Liposome | Paclitaxel | P2 |
| MAG‐CPT | Polymer conjugate | Camptothecin | P1 |
| LE‐SN‐38 | Liposome | SN‐38 | P2 |
| PK1 | Polymer conjugate | Doxorubicin | P2 |
| ,hT‐101 | Polymer conjugate | Camptothecin | P2 |
| SP1049C | Micelles | Doxorubicin | P3 |
| CPX‐1 | Liposome | CPT‐11,floxuridine | P2 |
|
Active targeting | |||
|---|---|---|---|
| Name | Platform | Compound | Clinical Stage |
| Mylotarg | Anti‐CD33‐Ab | Calicheamicin | Approved |
| Zevalin | Anti‐CD20‐Ab | 90Y | Approved |
| Bexxar | Anti‐CD20‐Ab | 131 I | Approved |
| PK2 | Galactose‐Polymer | Doxorubicin | P1 |
| MCC465 | Ab‐liposome | Doxorubicin | P1 |
| MBP‐426 | Transferrin‐liposome | Oxaliplatin | P1 |
| CALAA‐01 | Transferrin‐polymer | siRNA | P1 |
| T‐DM1 | Anti‐HER2‐Ab | DM1 | P1 |